ZVRA
Zevra Therapeutics, Inc.
Biotechnology
Market Cap$658M
5Y Perf.+270.0%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
ZVRA vs FOLD vs RARE vs ACAD
Revenue, margins, valuation, and 5-year total return — side by side.
FOLD
Amicus Therapeutics, Inc.
Biotechnology
Market Cap$4.55B
5Y Perf.+15.9%
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.57B
5Y Perf.-61.8%
ACAD
ACADIA Pharmaceuticals Inc.
Biotechnology
Market Cap$3.84B
5Y Perf.-54.9%
ZVRA vs FOLD vs RARE vs ACAD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ZVRA | FOLD | RARE | ACAD |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $658M | $4.55B | $2.57B | $3.84B |
| Revenue (TTM) | $122M | $634M | $669M | $1.10B |
| Net Income (TTM) | $124M | $-27M | $-609M | $376M |
| Gross Margin | 85.8% | 87.9% | 83.6% | 91.5% |
| Operating Margin | -4.4% | 5.2% | -83.9% | 7.4% |
| Forward P/E | 11.8x | 40.6x | — | 55.6x |
| Total Debt | $63M | $483M | $1.28B | $52M |
| Cash & Equiv. | $62M | $214M | $434M | $178M |
ZVRA vs FOLD vs RARE vs ACAD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ZVRA
FOLD
RARE
ACAD
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Zevra Therapeutics,… (ZVRA) | 100 | 370.0 | +270.0% |
| Amicus Therapeutics… (FOLD) | 100 | 115.9 | +15.9% |
| Ultragenyx Pharmace… (RARE) | 100 | 38.2 | -61.8% |
| ACADIA Pharmaceutic… (ACAD) | 100 | 45.1 | -54.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ZVRA vs FOLD vs RARE vs ACAD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ZVRA leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Amicus Therapeutics, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
ZVRA
Zevra Therapeutics, Inc.
The Growth Play
ZVRA carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- Rev growth 350.9%, EPS growth 159.2%, 3Y rev CAGR 118.8%
- Lower volatility, beta 0.62, Low D/E 40.9%, current ratio 5.68x
- Beta 0.62, current ratio 5.68x
- 350.9% revenue growth vs ACAD's 11.9%
Best for: growth exposure and sleep-well-at-night
FOLD
Amicus Therapeutics, Inc.
The Income Pick
FOLD is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- beta 0.61
- 119.2% 10Y total return vs ACAD's -23.4%
- Beta 0.61 vs RARE's 1.36
- +138.3% vs RARE's -27.4%
Best for: income & stability and long-term compounding
RARE
Ultragenyx Pharmaceutical Inc.
The Growth Angle
RARE plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
ACAD
ACADIA Pharmaceuticals Inc.
The Secondary Option
ACAD lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ZVRA | 350.9% revenue growth vs ACAD's 11.9% |
| Value | ZVRA | Better valuation composite |
| Quality / Margins | ZVRA | 101.6% margin vs RARE's -91.0% |
| Stability / Safety | FOLD | Beta 0.61 vs RARE's 1.36 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | FOLD | +138.3% vs RARE's -27.4% |
| Efficiency (ROA) | ZVRA | 45.6% ROA vs RARE's -45.8%, ROIC -2.9% vs -89.4% |
ZVRA vs FOLD vs RARE vs ACAD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2023
Segment breakdown not available.
FY 2025
FY 2018
ZVRA vs FOLD vs RARE vs ACAD — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACADLAGGINGRARE
Who Leads Where
ACAD leads in 2 of 6 categories
FOLD leads 1 • ZVRA leads 0 • RARE leads 0 • 2 tied
Explore the data ↓RAREUltragenyx Pharmaceut…
0leads
ZVRAZevra Therapeutics, I…
0leads
FOLDAmicus Therapeutics, …
1leads
ACADACADIA Pharmaceutical…
2leads
6 Total Categories
CATEGORYLEADERvs FOLDvs ZVRAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
ACAD4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ACAD6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
FOLD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — ZVRA and ACAD each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACAD is the larger business by revenue, generating $1.1B annually — 9.0x ZVRA's $122M. ZVRA is the more profitable business, keeping 101.6% of every revenue dollar as net income compared to RARE's -91.0%. On growth, ZVRA holds the edge at +77.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ZVRAZevra Therapeutic… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $122M | $634M | $669M | $1.1B |
| EBITDAEarnings before interest/tax | -$3M | $40M | -$536M | $96M |
| Net IncomeAfter-tax profit | $124M | -$27M | -$609M | $376M |
| Free Cash FlowCash after capex | $12M | $30M | -$487M | $212M |
| Gross MarginGross profit ÷ Revenue | +85.8% | +87.9% | +83.6% | +91.5% |
| Operating MarginEBIT ÷ Revenue | -4.4% | +5.2% | -83.9% | +7.4% |
| Net MarginNet income ÷ Revenue | +101.6% | -4.3% | -91.0% | +34.3% |
| FCF MarginFCF ÷ Revenue | +9.8% | +4.7% | -72.8% | +19.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +77.5% | +23.7% | -2.4% | +9.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +11.5% | -89.0% | -17.2% | -81.8% |
Evenly matched — ZVRA and ACAD each lead in 3 of 6 comparable metrics.
Valuation Metrics
ACAD leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 8.2x trailing earnings, ZVRA trades at a 16% valuation discount to ACAD's 9.8x P/E. On an enterprise value basis, ACAD's 26.7x EV/EBITDA is more attractive than FOLD's 114.9x.
| Metric | ZVRAZevra Therapeutic… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| Market CapShares × price | $658M | $4.5B | $2.6B | $3.8B |
| Enterprise ValueMkt cap + debt − cash | $659M | $4.8B | $3.4B | $3.7B |
| Trailing P/EPrice ÷ TTM EPS | 8.24x | -164.85x | -4.48x | 9.78x |
| Forward P/EPrice ÷ next-FY EPS est. | 11.80x | 40.62x | — | 55.62x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 114.88x | — | 26.71x |
| Price / SalesMarket cap ÷ Revenue | 6.18x | 7.17x | 3.82x | 3.58x |
| Price / BookPrice ÷ Book value/share | 4.12x | 16.29x | — | 3.13x |
| Price / FCFMarket cap ÷ FCF | — | 152.43x | — | 36.48x |
ACAD leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
ACAD leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
ZVRA delivers a 81.3% return on equity — every $100 of shareholder capital generates $81 in annual profit, vs $-6 for RARE. ACAD carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to FOLD's 1.76x. On the Piotroski fundamental quality scale (0–9), ZVRA scores 6/9 vs RARE's 4/9, reflecting solid financial health.
| Metric | ZVRAZevra Therapeutic… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | +81.3% | -12.0% | -6.1% | +35.6% |
| ROA (TTM)Return on assets | +45.6% | -3.2% | -45.8% | +26.2% |
| ROICReturn on invested capital | -2.9% | +5.3% | -89.4% | +10.0% |
| ROCEReturn on capital employed | -2.2% | +5.1% | -46.4% | +10.1% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 4 | 6 |
| Debt / EquityFinancial leverage | 0.41x | 1.76x | — | 0.04x |
| Net DebtTotal debt minus cash | $800,000 | $269M | $842M | -$126M |
| Cash & Equiv.Liquid assets | $62M | $214M | $434M | $178M |
| Total DebtShort + long-term debt | $63M | $483M | $1.3B | $52M |
| Interest CoverageEBIT ÷ Interest expense | 22.02x | 1.00x | -14.49x | — |
ACAD leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — ZVRA and FOLD each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in FOLD five years ago would be worth $15,431 today (with dividends reinvested), compared to $2,391 for RARE. Over the past 12 months, FOLD leads with a +138.3% total return vs RARE's -27.4%. The 3-year compound annual growth rate (CAGR) favors ZVRA at 31.3% vs RARE's -17.8% — a key indicator of consistent wealth creation.
| Metric | ZVRAZevra Therapeutic… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +33.5% | +1.5% | +10.7% | -14.3% |
| 1-Year ReturnPast 12 months | +42.9% | +138.3% | -27.4% | +32.3% |
| 3-Year ReturnCumulative with dividends | +126.2% | +19.0% | -44.5% | +3.9% |
| 5-Year ReturnCumulative with dividends | +25.2% | +54.3% | -76.1% | +6.6% |
| 10-Year ReturnCumulative with dividends | -90.8% | +119.2% | -59.4% | -23.4% |
| CAGR (3Y)Annualised 3-year return | +31.3% | +6.0% | -17.8% | +1.3% |
Evenly matched — ZVRA and FOLD each lead in 3 of 6 comparable metrics.
Risk & Volatility
FOLD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
FOLD is the less volatile stock with a 0.61 beta — it tends to amplify market swings less than RARE's 1.36 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FOLD currently trades 99.9% from its 52-week high vs RARE's 61.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ZVRAZevra Therapeutic… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.62x | 0.61x | 1.36x | 1.11x |
| 52-Week HighHighest price in past year | $13.16 | $14.50 | $42.37 | $27.81 |
| 52-Week LowLowest price in past year | $7.16 | $5.51 | $18.29 | $14.68 |
| % of 52W HighCurrent price vs 52-week peak | +84.6% | +99.9% | +61.6% | +80.5% |
| RSI (14)Momentum oscillator 0–100 | 63.1 | 72.2 | 67.7 | 53.8 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 2.9M | 1.8M | 1.7M |
FOLD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ZVRA as "Buy", FOLD as "Buy", RARE as "Buy", ACAD as "Buy". Consensus price targets imply 129.1% upside for ZVRA (target: $26) vs 0.1% for FOLD (target: $15).
| Metric | ZVRAZevra Therapeutic… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $25.50 | $14.50 | $48.36 | $34.78 |
| # AnalystsCovering analysts | 8 | 24 | 33 | 37 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACAD leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). FOLD leads in 1 (Risk & Volatility). 2 tied.
Best OverallACADIA Pharmaceuticals Inc. (ACAD)Leads 2 of 6 categories
Loading custom metrics...
ZVRA vs FOLD vs RARE vs ACAD: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ZVRA or FOLD or RARE or ACAD a better buy right now?
For growth investors, Zevra Therapeutics, Inc.
(ZVRA) is the stronger pick with 350. 9% revenue growth year-over-year, versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). Zevra Therapeutics, Inc. (ZVRA) offers the better valuation at 8. 2x trailing P/E (11. 8x forward), making it the more compelling value choice. Analysts rate Zevra Therapeutics, Inc. (ZVRA) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ZVRA or FOLD or RARE or ACAD?
On trailing P/E, Zevra Therapeutics, Inc.
(ZVRA) is the cheapest at 8. 2x versus ACADIA Pharmaceuticals Inc. at 9. 8x. On forward P/E, Zevra Therapeutics, Inc. is actually cheaper at 11. 8x.
03Which is the better long-term investment — ZVRA or FOLD or RARE or ACAD?
Over the past 5 years, Amicus Therapeutics, Inc.
(FOLD) delivered a total return of +54. 3%, compared to -76. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: FOLD returned +119. 2% versus ZVRA's -90. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ZVRA or FOLD or RARE or ACAD?
By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.
(FOLD) is the lower-risk stock at 0. 61β versus Ultragenyx Pharmaceutical Inc. 's 1. 36β — meaning RARE is approximately 123% more volatile than FOLD relative to the S&P 500. On balance sheet safety, ACADIA Pharmaceuticals Inc. (ACAD) carries a lower debt/equity ratio of 4% versus 176% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — ZVRA or FOLD or RARE or ACAD?
By revenue growth (latest reported year), Zevra Therapeutics, Inc.
(ZVRA) is pulling ahead at 350. 9% versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). On earnings-per-share growth, the picture is similar: Zevra Therapeutics, Inc. grew EPS 159. 2% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Over a 3-year CAGR, ZVRA leads at 118. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ZVRA or FOLD or RARE or ACAD?
Zevra Therapeutics, Inc.
(ZVRA) is the more profitable company, earning 78. 2% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 78. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -79. 5% for RARE. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ZVRA or FOLD or RARE or ACAD more undervalued right now?
On forward earnings alone, Zevra Therapeutics, Inc.
(ZVRA) trades at 11. 8x forward P/E versus 55. 6x for ACADIA Pharmaceuticals Inc. — 43. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ZVRA: 129. 1% to $25. 50.
08Which pays a better dividend — ZVRA or FOLD or RARE or ACAD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is ZVRA or FOLD or RARE or ACAD better for a retirement portfolio?
For long-horizon retirement investors, Amicus Therapeutics, Inc.
(FOLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 61), +119. 2% 10Y return). Both have compounded well over 10 years (FOLD: +119. 2%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ZVRA and FOLD and RARE and ACAD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ZVRA is a small-cap high-growth stock; FOLD is a small-cap high-growth stock; RARE is a small-cap high-growth stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(ZVRA: 77.5% · FOLD: 23.7%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.